Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

Many chronic pain patients can reduce opioid use with slow, voluntary taper (opens in a new tab)

med.stanford.edu · 2026-07-09

Short answerEvidenceSource

Short answer

Mixed

Mixed.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

  • 3 supported
  • 3 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

Every claim we could check holds up. Three of six claims match the study. This overall rating is based only on the claims we could check. Three claims the study doesn't address.

  • 3 supported
  • 3 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

6 claims in this story

Showing all 6 claimsChoose a verdict to focus the list.

Claim 1 of 6Not coveredThe study enrolled more than 500 adults with pain for at least six months who had taken prescription opioids for at least three months, with an average of 12.4 years of opioid use, and used a personalized tapering plan over 12 months in which doses were reduced by no more than 10% per month.View evidenceHide evidence

As statedmore than 500 adults; 12.4 years on average; no more than 10% per month

Why this verdict

The abstract profile supports several elements: n=562 adults, chronic pain for at least 6 months, prescription opioid exposure for at least 3 months, and 12-month patient-centered tapering. However, the supplied abstract profile does not verify the stated average 12.4 years of opioid use or the specific taper limit of no more than 10% per month. Those may be in the full paper or news story, but they are not verifiable from the abstract-depth profile.

1

Study evidence

Taper success rates at 12 months were similar across arms: taper only 50.9% (95% CI, 42.9% to 58.9%), taper + pain-CBT 48.6% (95% CI, 41.0% to 56.2%), taper + CPSMP 44.5% (95% CI, 36.0% to 53.3%).Taper only 50.9% (95% CI 42.9–58.9%); taper+pain-CBT 48.6% (95% CI 41.0–56.2%); taper+CPSMP 44.5% (95% CI 36.0–53.3%)

“DESIGN: Randomized controlled trial.”
Claim 2 of 6Not coveredThe researchers found that adding supportive therapies did not increase opioid tapering success, but cognitive behavioral therapy for chronic pain seemed to lessen opioid withdrawal symptoms; the article says those assigned to cognitive behavioral therapy reported about half as many withdrawal symptoms as the taper-only group.View evidenceHide evidence

As statedabout half as many withdrawal symptoms

Why this verdict

The abstract profile supports that adjunct CBT and CPSMP did not improve 12-month taper success versus taper only. It also supports that study-related adverse events, including opioid withdrawal symptoms, were lower in the pain-CBT arm than taper only, and that CBT may reduce adverse effects. However, the specific statement that CBT participants reported about half as many withdrawal symptoms as taper-only participants is not verifiable from the abstract profile, which reports only overall study-related adverse event risk including withdrawal symptoms, not withdrawal-specific symptom counts.

1

Study evidence

Taper success rates at 12 months were similar across arms: taper only 50.9% (95% CI, 42.9% to 58.9%), taper + pain-CBT 48.6% (95% CI, 41.0% to 56.2%), taper + CPSMP 44.5% (95% CI, 36.0% to 53.3%).Taper only 50.9% (95% CI 42.9–58.9%); taper+pain-CBT 48.6% (95% CI 41.0–56.2%); taper+CPSMP 44.5% (95% CI 36.0–53.3%)

“DESIGN: Randomized controlled trial.”
2

Study evidence

Study-related adverse event risk (including opioid withdrawal symptoms) was highest in the taper-only group (126/191, 66%) compared with taper plus pain-CBT (109/203, 54%) and taper plus CPSMP (108/168, 64%).66% vs 54% (12 percentage points higher vs pain-CBT); 66% vs 64% (2 percentage points higher vs CPSMP)

“Study-related adverse event risk (including opioid withdrawal symptoms) was highest in the taper only group (126 of 191 [66%]) compared with taper plus pain-CBT (109 of 203 [54%]) and taper plus CPSMP (108 of 168 [64%]).”
Claim 3 of 6Not coveredThe article says patient readiness to taper at the start of the study was a good predictor of taper success, and it notes that the program was not designed for people with opioid addiction and excluded patients with moderate or severe opioid use disorder.View evidenceHide evidence

Why this verdict

The abstract profile supports that participants with moderate or severe opioid use disorder were excluded, so the study was not designed to generalize to that population. But the claim that baseline readiness to taper was a good predictor of taper success is not present in the abstract-depth profile and therefore cannot be verified at this evidence depth.

1

Study evidence

Taper success rates at 12 months were similar across arms: taper only 50.9% (95% CI, 42.9% to 58.9%), taper + pain-CBT 48.6% (95% CI, 41.0% to 56.2%), taper + CPSMP 44.5% (95% CI, 36.0% to 53.3%).Taper only 50.9% (95% CI 42.9–58.9%); taper+pain-CBT 48.6% (95% CI 41.0–56.2%); taper+CPSMP 44.5% (95% CI 36.0–53.3%)

“DESIGN: Randomized controlled trial.”
Claim 4 of 6SupportedA new large-scale study led by Stanford Medicine suggests that many chronic pain patients may be able to reduce their opioid use long term without increasing their pain if tapering is done with the right approach.View evidenceHide evidence

As statedmany patients

Why this verdict

The abstract-level profile supports a hedged associational statement that many adults with chronic pain on long-term prescription opioids achieved 12-month taper success under a patient-centered tapering approach, with taper success defined to avoid increased pain or involve decreased pain. The paper profile reports about half achieving taper success across arms. The claim would be too broad if applied to patients with moderate or severe opioid use disorder, but the story reportedly notes that exclusion.

1

Study evidence

Taper success rates at 12 months were similar across arms: taper only 50.9% (95% CI, 42.9% to 58.9%), taper + pain-CBT 48.6% (95% CI, 41.0% to 56.2%), taper + CPSMP 44.5% (95% CI, 36.0% to 53.3%).Taper only 50.9% (95% CI 42.9–58.9%); taper+pain-CBT 48.6% (95% CI 41.0–56.2%); taper+CPSMP 44.5% (95% CI 36.0–53.3%)

“DESIGN: Randomized controlled trial.”
Claim 5 of 6SupportedAfter 12 months, about half of participants had a successful response, defined as cutting opioid dose by at least 50% without increased pain or staying at the same dose with significantly less pain.View evidenceHide evidence

As statedabout half; 50% dose reduction

Why this verdict

The abstract profile directly supports this claim. Taper success was defined as either at least a 50% MEDD decrease with no increased pain or no MEDD increase with decreased pain intensity, and reported rates were roughly half in the taper-only and CBT arms and 44.5% in the CPSMP arm.

1

Study evidence

Taper success rates at 12 months were similar across arms: taper only 50.9% (95% CI, 42.9% to 58.9%), taper + pain-CBT 48.6% (95% CI, 41.0% to 56.2%), taper + CPSMP 44.5% (95% CI, 36.0% to 53.3%).Taper only 50.9% (95% CI 42.9–58.9%); taper+pain-CBT 48.6% (95% CI 41.0–56.2%); taper+CPSMP 44.5% (95% CI 36.0–53.3%)

“DESIGN: Randomized controlled trial.”
Claim 6 of 6SupportedThe study compared tapering alone with tapering plus cognitive behavioral therapy for chronic pain or tapering plus a peer-led chronic pain self-management program.View evidenceHide evidence

As statedone-third in each group; eight weekly sessions; six weekly sessions

Why this verdict

The abstract profile supports that participants were randomized to three strategies: patient-centered taper only, taper plus cognitive behavioral therapy for chronic pain, or taper plus chronic pain self-management program. Randomized group sizes were 191, 203, and 168, approximately one-third in each arm. Session-count details, if asserted elsewhere in the story, are not present in the abstract-depth profile.

1

Study evidence

Taper success rates at 12 months were similar across arms: taper only 50.9% (95% CI, 42.9% to 58.9%), taper + pain-CBT 48.6% (95% CI, 41.0% to 56.2%), taper + CPSMP 44.5% (95% CI, 36.0% to 53.3%).Taper only 50.9% (95% CI 42.9–58.9%); taper+pain-CBT 48.6% (95% CI 41.0–56.2%); taper+CPSMP 44.5% (95% CI 36.0–53.3%)

“DESIGN: Randomized controlled trial.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • COVID-19–related challenges reduced sample size and produced treatment-group imbalances, which may affect precision and comparability.

    This interpretation-relevant limitation is listed in the paper profile but is not included among the story caveats supplied.

    From Randomized controlled trial; Randomized controlled trial

  • Low behavioral treatment attendance and losses to follow-up could have limited observed effectiveness of adjunct interventions.

    The story caveats mention relatively low participation in supportive therapies, but they do not mention losses to follow-up. Because both attendance and follow-up loss affect interpretation of the adjunct-therapy results, this limitation is only partially reflected and is marked as not fully reflected.

    From Randomized controlled trial; Randomized controlled trial

  • The abstract profile provides limited detail on pain measurement instruments and adverse-event ascertainment, severity, timing, and statistical testing.

    These abstract-level evidence limitations are not mentioned in the story caveats, and they matter particularly for interpreting pain and withdrawal/adverse-event claims.

    From Randomized controlled trial; Randomized controlled trial

5 things the story did carry across
  • The paper was a three-arm, multi-site randomized controlled trial at 11 U.S. sites comparing patient-centered taper only, taper plus pain-CBT, and taper plus CPSMP.
  • The study population consisted of adults with chronic pain for at least 6 months receiving long-term prescription opioids, with moderate or severe opioid use disorder excluded.
  • The primary outcome was 12-month taper success, defined by opioid dose change and pain intensity change: at least 50% MEDD reduction with no increased pain, or no MEDD increase with decreased pain intensity.
  • Taper success rates were similar across arms: 50.9% taper only, 48.6% taper plus pain-CBT, and 44.5% taper plus CPSMP, with confidence intervals crossing no meaningful advantage for adjuncts.
  • Study-related adverse events, including opioid withdrawal symptoms, were reported more often in taper only than taper plus pain-CBT, but abstract-level data report overall study-related adverse events rather than withdrawal-specific symptom counts.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

2

Evidence read

study summary

Lead result

human in vivo

1Lead resulthuman in vivoCompare effectiveness of three patient-centered outpatient opioid tapering strategies (taper only vs taper+pain-CBT vs taper+CPSMP) on 12-month taper success in adults on long-term prescription opioids.Randomized controlled trialExpand

In plain English

Multi-site randomized trial (n=562) comparing patient-centered opioid tapering alone versus taper plus cognitive behavioral therapy (pain-CBT) or a chronic pain self-management program (CPSMP) found similar 12-month taper success across arms; behavioral adjuncts did not improve taper success, while CBT was associated with fewer study-related adverse events.

Key findings

  • Taper success rates at 12 months were similar across arms: taper only 50.9% (95% CI, 42.9% to 58.9%), taper + pain-CBT 48.6% (95% CI, 41.0% to 56.2%), taper + CPSMP 44.5% (95% CI, 36.0% to 53.3%).Taper only 50.9% (95% CI 42.9–58.9%); taper+pain-CBT 48.6% (95% CI 41.0–56.2%); taper+CPSMP 44.5% (95% CI 36.0–53.3%)
  • Between-group differences in taper success versus taper only were small and imprecise: taper + pain-CBT vs taper only −2.4 percentage points (95% CI, −11.9 to 7.2); taper + CPSMP vs taper only −5.2 percentage points (95% CI, −15.3 to 4.8).Pain-CBT vs taper only: −2.4 percentage points (95% CI −11.9 to 7.2); CPSMP vs taper only: −5.2 percentage points (95% CI −15.3 to 4.8)
“DESIGN: Randomized controlled trial.”
What this piece can’t prove
  • COVID-19–related challenges reduced sample size and resulted in imbalanced treatment groups (not quantified in abstract).
  • Low behavioral treatment attendance and losses to follow-up could have limited the observed effectiveness of adjunct interventions.
  • Participants with moderate or severe opioid use disorder were excluded; results may not generalize to that population.

1 further detail could not be confirmed from the summary.

2human in vivoCompare harms/safety (study-related adverse events including opioid withdrawal symptoms) across the three tapering strategy groups.Randomized controlled trialExpand

In plain English

In this randomized trial of three outpatient, patient-centered opioid tapering strategies, study-related adverse event risk (including opioid withdrawal symptoms) was reported by arm and was highest in the taper-only arm (126/191, 66%) versus taper plus pain-CBT (109/203, 54%) and taper plus CPSMP (108/168, 64%). The abstract notes a possible reduction in adverse effects with addition of CBT.

Key findings

  • Study-related adverse event risk (including opioid withdrawal symptoms) was highest in the taper-only group (126/191, 66%) compared with taper plus pain-CBT (109/203, 54%) and taper plus CPSMP (108/168, 64%).66% vs 54% (12 percentage points higher vs pain-CBT); 66% vs 64% (2 percentage points higher vs CPSMP)
“Study-related adverse event risk (including opioid withdrawal symptoms) was highest in the taper only group (126 of 191 [66%]) compared with taper plus pain-CBT (109 of 203 [54%]) and taper plus CPSMP (108 of 168 [64%]).”
What this piece can’t prove
  • Abstract states COVID-19–related challenges reduced the sample size and produced treatment-group imbalances.
  • The abstract provides limited detail on adverse event ascertainment, definitions, severity grading, and statistical comparison reporting.

1 further detail could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 15 candidate papers

And 9 more candidates considered.